Equities

Healthequity Inc

Healthequity Inc

Actions
Health CareHealth Care Providers
  • Price (USD)78.27
  • Today's Change0.73 / 0.94%
  • Shares traded249.87k
  • 1 Year change+10.32%
  • Beta0.5244
Data delayed at least 15 minutes, as of Sep 19 2024 20:10 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Sep-23
  • 20-Jun-24
  • 18-Jul-24
  • 15-Aug-24
  • 12-Sep-24
Select bar for recommendation details.
Recommendations12-Sep-24
Buy6
Outperform8
Hold0
Sell0
Strong Sell0

Share price forecast in USD

The 13 analysts offering 12 month price targets for Healthequity Inc have a median target of 104.00, with a high estimate of 110.00 and a low estimate of 95.00. The median estimate represents a 34.12% increase from the last price of 77.54.
High41.9%110.00
Med34.1%104.00
Low22.5%95.00

Earnings history & estimates in USD

On Sep 03, 2024, Healthequity Inc reported 2nd quarter 2025 earnings of 0.86 per share. This result exceeded the 0.70 consensus of the 13 analysts covering the company and exceeded last year's 2nd quarter results by 62.26%.
The next earnings announcement is expected on Dec 03, 2024.
Average growth rate+13.17%
Healthequity Inc reported annual 2024 earnings of 2.25 per share on Mar 19, 2024.
Average growth rate+11.69%
More ▼

Revenue history & estimates in USD

HealthEquity, Inc. had 2nd quarter 2025 revenues of 299.93m. This bettered the 284.87m consensus of the 12 analysts covering the company. This was 22.70% above the prior year's 2nd quarter results.
Average growth rate+5.38%
HealthEquity, Inc. had revenues for the full year 2024 of 999.59m. This was 16.00% above the prior year's results.
Average growth rate+17.73%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.